Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review

Ovarian cancer is the 5th leading cause of death for women with cancer worldwide. In more than 70% of cases, it is only diagnosed at an advanced stage. Our study aims to give an update on the biological markers for diagnosing ovarian cancer, specifically HE4, CA 125, RMI and ROMA algorithms.Serum CA125 assay has low sensitivity in the early stages and can be increased in certain conditions such as menstruation or endometriosis. The level of HE4 is overexpressed in ovarian tumors. Its specificity is 94% and its level is not affected by endometriosis cysts. The combined measures of CA125 and HE4 have proved to be highly efficient with an area under the curve (AUC) of up to 0.96. Furthermore, this combined measure of CA125 can correct the variations in HE4 which are due to smoking or contraception combining estrogen plus progestin. While the specificity of RMI sometimes reaches 92%, the rather low AUC of 0.86 does not make it the best diagnostic tool. The specificity of ROMA is lower than HE4 (84% compared to 94%).To date, the most efficient biological diagnostic tool to diagnose ovarian cancer is the combination of CA125 and HE4.

[1]  Markman.  The Role of CA-125 in the Management of Ovarian Cancer. , 1997, The oncologist.

[2]  B. van Calster,et al.  Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. , 2012, European journal of cancer.

[3]  F. Ramadhan,et al.  Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass. , 2016, Oman medical journal.

[4]  G. Anderson,et al.  Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[5]  M. Panteghini,et al.  Body mass index does not influence human epididymis protein 4 concentrations in serum. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[6]  B. Karlan,et al.  Interpretation of Single and Serial Measures of HE4 and CA125 in Asymptomatic Women at High Risk for Ovarian Cancer , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[7]  R. Knapp,et al.  Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. , 2011, American journal of obstetrics and gynecology.

[8]  J. Kaur,et al.  An Evaluation of the Applicability of the Risk of Malignancy Index for Adnexal Masses to Patients Seen at a Tertiary Hospital in Chandigarh, India , 2015, The Journal of Obstetrics and Gynecology of India.

[9]  Charles W Drescher,et al.  Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. , 2010, Gynecologic oncology.

[10]  Steven J Skates,et al.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. , 2009, Gynecologic oncology.

[11]  X. Fritel,et al.  Recommandations pour la pratique clinique : tumeurs ovariennes présumées bénignes – Objectifs, méthodes et organisation , 2013 .

[12]  M. Panteghini,et al.  Verification of the harmonization of human epididymis protein 4 assays , 2016, Clinical chemistry and laboratory medicine.

[13]  Thorsten Verch,et al.  The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. , 2008, Gynecologic oncology.

[14]  L. Bian,et al.  Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis. , 2014, Molecular and clinical oncology.

[15]  Michèl Schummer,et al.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. , 2003, Cancer research.

[16]  R. Bast,et al.  Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. , 2010, Gynecologic oncology.

[17]  T. Bourne,et al.  Prognostic Value of Serum HE4 Levels and Risk of Ovarian Malignancy Algorithm Scores at the Time of Ovarian Cancer Diagnosis , 2014, International Journal of Gynecologic Cancer.

[18]  L. Frati,et al.  The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer , 2013, Journal of Ovarian Research.

[19]  D Timmerman,et al.  Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. , 2016, European journal of cancer.

[20]  J. Brun,et al.  Marqueurs sériques et tumoraux ovariens dans le diagnostic des tumeurs ovariennes présumées bénignes , 2013 .

[21]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983 .

[22]  Richard G. Moore,et al.  Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. , 2012, American journal of obstetrics and gynecology.

[23]  M. Panteghini,et al.  Is serum human epididymis protein 4 ready for prime time? , 2014, Annals of clinical biochemistry.

[24]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[25]  Hongwen Yao,et al.  Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis , 2014, Tumor Biology.

[26]  A. Chudecka-Głaz,et al.  ROMA, an algorithm for ovarian cancer. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[27]  H. Labib,et al.  HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[28]  Edmund Chada Baracat,et al.  A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses , 2012, Clinics.

[29]  T. Maggino,et al.  HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. , 2016, Gynecologic oncology.

[30]  M. Neradilek,et al.  Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. , 2017, Gynecologic oncology.

[31]  Bei Zhang,et al.  The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer , 2016, Biomedical reports.

[32]  A. Colak,et al.  Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer. , 2015, European journal of gynaecological oncology.

[33]  P. Bossuyt,et al.  Blood biomarkers for the non-invasive diagnosis of endometriosis. , 2016, The Cochrane database of systematic reviews.

[34]  Tingting Zhao,et al.  CA125 and HE4: Measurement Tools for Ovarian Cancer , 2016, Gynecologic and Obstetric Investigation.

[35]  I. Meinhold-Heerlein,et al.  The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer , 2014, Archives of Gynecology and Obstetrics.

[36]  S. Skates,et al.  Blood and Urine Markers for Ovarian Cancer: A Comprehensive Review , 2004, Disease markers.

[37]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[38]  Massimo Candiani,et al.  Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. , 2013, Gynecologic oncology.

[39]  T. Bourne,et al.  External Validation of Diagnostic Models to Estimate the Risk of Malignancy in Adnexal Masses , 2011, Clinical Cancer Research.

[40]  R. Ivell,et al.  A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. , 1991, Biology of reproduction.

[41]  P Maisonneuve,et al.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[42]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[43]  A. Omigbodun,et al.  Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index , 2009, The journal of obstetrics and gynaecology research.

[44]  H. Frierson,et al.  Comprehensive analysis of HE4 expression in normal and malignant human tissues , 2006, Modern Pathology.

[45]  N. Lahlou,et al.  [Ovarian tumor markers of presumed benign ovarian tumors]. , 2013, Journal de gynecologie, obstetrique et biologie de la reproduction.

[46]  Hys Ngan,et al.  Carcinoma of the Ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[47]  R. Bast,et al.  Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.

[48]  M. Plebani.  HE4 in gynecological cancers: report of a European investigators and experts meeting , 2012, Clinical chemistry and laboratory medicine.

[49]  L. Sarian,et al.  Performance of the Risk of Malignancy Index for Discriminating Malignant Tumors in Women With Adnexal Masses , 2016, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[50]  Fake Li,et al.  Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: A meta-analysis , 2012, BMC Cancer.

[51]  M. Panteghini,et al.  Human epididymis protein 4: factors of variation. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[52]  H. Kafalı,et al.  Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle , 2007, Archives of Gynecology and Obstetrics.

[53]  P. Buamah.  Benign conditions associated with raised serum CA‐125 concentration , 2000, Journal of surgical oncology.

[54]  Christopher P Crum,et al.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.

[55]  K. Khan,et al.  Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta‐analysis , 2016, BJOG : an international journal of obstetrics and gynaecology.

[56]  C. Duan,et al.  Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[57]  M. Panteghini,et al.  Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review , 2013, Journal of Clinical Pathology.

[58]  N. Hacker,et al.  Improved Detection Rate of Ovarian Cancer Using a 2-Step Triage Model of the Risk of Malignancy Index and Expert Sonography in an Outpatient Screening Setting , 2016, International Journal of Gynecologic Cancer.

[59]  A. Chudecka-Głaz,et al.  Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status? , 2016, Tumor Biology.

[60]  Charles W Drescher,et al.  Potential role of HE4 in multimodal screening for epithelial ovarian cancer. , 2011, Journal of the National Cancer Institute.

[61]  B. Thinkhamrop,et al.  Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses? , 2016, Gynecologic and Obstetric Investigation.

[62]  B. Karlan,et al.  Ovarian cancer screening. , 2003, Hematology/oncology clinics of North America.

[63]  K. Nustad,et al.  Human epididymis protein 4 reference limits and natural variation in a Nordic reference population , 2011, Tumor Biology.

[64]  A. Ghaderi,et al.  Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women , 2008, Pathology & Oncology Research.

[65]  I. Gram,et al.  Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort , 2017, Journal of Ovarian Research.

[66]  M. Poutanen,et al.  Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts , 2009, British Journal of Cancer.

[67]  R. Bast,et al.  The role of biomarkers in the management of epithelial ovarian cancer , 2017, Expert review of molecular diagnostics.

[68]  T. Aw,et al.  Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings , 2015, Journal of gynecologic oncology.

[69]  Josef Chovanec,et al.  A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass. , 2015, Gynecologic oncology.

[70]  Y. Bourbonnais,et al.  Proteins with whey-acidic-protein motifs and cancer. , 2006, The Lancet. Oncology.

[71]  A. E. Sippel,et al.  Mouse whey acidic protein is a novel member of the family of 'four-disulfide core' proteins. , 1982, Nucleic acids research.

[72]  J. Chan,et al.  Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. , 2008, Gynecologic oncology.

[73]  I. Jacobs,et al.  A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer , 1990 .